Selumetinib plus docetaxel compared with docetaxel alone and progression-free survival in patients with KRAS-mutant advanced non-small cell lung cancer: The SELECT-1 randomized clinical trial

  1. Jänne, P.A.
  2. Van Den Heuvel, M.M.
  3. Barlesi, F.
  4. Cobo, M.
  5. Mazieres, J.
  6. Crinò, L.
  7. Orlov, S.
  8. Blackhall, F.
  9. Wolf, J.
  10. Garrido, P.
  11. Poltoratskiy, A.
  12. Mariani, G.
  13. Ghiorghiu, D.
  14. Kilgour, E.
  15. Smith, P.
  16. Kohlmann, A.
  17. Carlile, D.J.
  18. Lawrence, D.
  19. Bowen, K.
  20. Vansteenkiste, J.
Aldizkaria:
JAMA - Journal of the American Medical Association

ISSN: 1538-3598 0098-7484

Argitalpen urtea: 2017

Alea: 317

Zenbakia: 18

Orrialdeak: 1844-1853

Mota: Artikulua

DOI: 10.1001/JAMA.2017.3438 GOOGLE SCHOLAR

Garapen Iraunkorreko Helburuak